PMID- 28114978
OWN - NLM
STAT- MEDLINE
DCOM- 20170220
LR  - 20191210
IS  - 1470-7330 (Electronic)
IS  - 1740-5025 (Print)
IS  - 1470-7330 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Jan 23
TI  - CT texture analysis: a potential tool for prediction of survival in patients with 
      metastatic clear cell carcinoma treated with sunitinib.
PG  - 4
LID - 10.1186/s40644-017-0106-8 [doi]
LID - 4
AB  - BACKGROUND: To assess CT texture based quantitative imaging biomarkers in the 
      prediction of progression free survival (PFS) and overall survival (OS) in 
      patients with clear cell renal cell carcinoma undergoing treatment with 
      Sunitinib. METHODS: In this retrospective study, measurable lesions of 40 
      patients were selected based on RECIST criteria on standard contrast enhanced CT 
      before and 2 months after treatment with Sunitinib. CT Texture analysis was 
      performed using TexRAD research software (TexRAD Ltd, Cambridge, UK). Using a Cox 
      regression model, correlation of texture parameters with measured time to 
      progression and overall survival were assessed. Evaluation of combined 
      International Metastatic Renal-Cell Carcinoma Database Consortium Model (IMDC) 
      score with texture parameters was also performed. RESULTS: Size normalized 
      standard deviation (nSD) alone at baseline and follow-up after treatment was a 
      predictor of OS (Hazard ratio (HR) = 0.01 and 0.02; 95% confidence intervals 
      (CI): 0.00 - 0.29 and 0.00 - 0.39; p = 0.01 and 0.01). Entropy following 
      treatment and entropy change before and after treatment were both significant 
      predictors of OS (HR = 2.68 and 87.77; 95% CI = 1.14 - 6.29 and 1.26 - 6115.69; 
      p = 0.02 and p = 0.04). nSD was also a predictor of PFS at baseline and follow-up 
      (HR = 0.01 and 0.01: 95% CI: 0.00 - 0.31 and 0.001 - 0.22; p = 0.01 and 
      p = 0.003). When nSD at baseline or at follow-up was combined with IMDC, it 
      improved the association with OS and PFS compared to IMDC alone. CONCLUSION: Size 
      normalized standard deviation from CT at baseline and follow-up scans is 
      correlated with OS and PFS in clear cell renal cell carcinoma treated with 
      Sunitinib.
FAU - Haider, Masoom A
AU  - Haider MA
AD  - Department of Medical Imaging, Sunnybrook Health Sciences Center, University of 
      Toronto, Rm AG-46, 2075 Bayview Ave, Toronto, Onatrio, M4N 3M5, Canada. 
      masoom.haider@sunnybrook.ca.
FAU - Vosough, Alireza
AU  - Vosough A
AD  - Department of Radiology, North Bristol NHS Trust, Southmead Hospital, Bristol, 
      UK.
FAU - Khalvati, Farzad
AU  - Khalvati F
AD  - Department of Medical Imaging, Sunnybrook Health Sciences Center, University of 
      Toronto, Rm AG-46, 2075 Bayview Ave, Toronto, Onatrio, M4N 3M5, Canada.
FAU - Kiss, Alexander
AU  - Kiss A
AD  - Sunnybrook Health Sciences Center, Toronto, Canada.
FAU - Ganeshan, Balaji
AU  - Ganeshan B
AD  - Institute of Nuclear Medicine, University College London, London, UK.
FAU - Bjarnason, Georg A
AU  - Bjarnason GA
AD  - Sunnybrook Odette Cancer Centre, Division of medical Oncology, University of 
      Toronto, Toronto, ON, Canada.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20170123
PL  - England
TA  - Cancer Imaging
JT  - Cancer imaging : the official publication of the International Cancer Imaging 
      Society
JID - 101172931
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Renal Cell/*diagnostic imaging/drug therapy/pathology
MH  - Female
MH  - Humans
MH  - Indoles/*therapeutic use
MH  - Kidney Neoplasms/*diagnostic imaging/drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Predictive Value of Tests
MH  - Pyrroles/*therapeutic use
MH  - Radiographic Image Enhancement/*methods
MH  - Sunitinib
MH  - Tomography, X-Ray Computed/*methods
MH  - Treatment Outcome
PMC - PMC5259868
OTO - NOTNLM
OT  - CT image features
OT  - CT texture analysis
OT  - Metastatic clear cell carcinoma
OT  - Prediction of outcome
OT  - Quantitative imaging biomarkers
EDAT- 2017/01/25 06:00
MHDA- 2017/08/18 06:00
PMCR- 2017/01/23
CRDT- 2017/01/25 06:00
PHST- 2016/09/16 00:00 [received]
PHST- 2017/01/10 00:00 [accepted]
PHST- 2017/01/25 06:00 [entrez]
PHST- 2017/01/25 06:00 [pubmed]
PHST- 2017/08/18 06:00 [medline]
PHST- 2017/01/23 00:00 [pmc-release]
AID - 10.1186/s40644-017-0106-8 [pii]
AID - 106 [pii]
AID - 10.1186/s40644-017-0106-8 [doi]
PST - epublish
SO  - Cancer Imaging. 2017 Jan 23;17(1):4. doi: 10.1186/s40644-017-0106-8.